Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PT Kimia Farma Persero Tbk's Revenue for the
three
months ended in Jun. 2026 was Rp2,671,041 Mil. PT Kimia Farma Persero Tbk's average Accounts Receivable for the
three
months ended in Jun. 2026 was Rp1,310,839 Mil.
Hence, PT Kimia Farma Persero Tbk's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.04.
PT Kimia Farma Persero Tbk (ISX:KAEF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PT Kimia Farma Persero Tbk Receivables Turnover Related Terms
PT Kimia Farma Persero Tbk Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk Receivables Turnover Chart
ISX:KAEF vs MCK, COR, CAH: Receivables Turnover Comparison
For the Medical Distribution subindustry, PT Kimia Farma Persero Tbk's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Persero Tbk Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Persero Tbk's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Persero Tbk's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk (ISX:KAEF) has a Receivables Turnover of 2.04 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PT Kimia Farma Persero Tbk and its competitors. According to the industry distribution chart, PT Kimia Farma Persero Tbk ranks #28 out of 118 companies in the Medical Distribution industry, placing it in the top 23.7%.
Is PT Kimia Farma Persero Tbk's Receivables Turnover too high?
PT Kimia Farma Persero Tbk's current Receivables Turnover is 2.04. The Medical Distribution industry median Receivables Turnover is 4.72. PT Kimia Farma Persero Tbk's value of 2.04 is 56.8% below this industry median. Based on the distribution chart, PT Kimia Farma Persero Tbk ranks #28 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's Receivables Turnover compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Persero Tbk ranks #28 out of 118 companies for Receivables Turnover. This places PT Kimia Farma Persero Tbk in the top 24% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 4.72. PT Kimia Farma Persero Tbk's value of 2.04 is 56.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.72, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Persero Tbk's current Receivables Turnover of 2.04 is 56.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PT Kimia Farma Persero Tbk and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Persero Tbk's current Receivables Turnover is 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp579.75, compared to a current price of Rp442.00 — trading 23.8% below its estimated fair value. The current Receivables Turnover is 2.04 and 56.8% below the Medical Distribution industry median of 4.72. PT Kimia Farma Persero Tbk's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current Receivables Turnover is 2.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp442.00 is trading 23.8% below its estimated GF Value™ of Rp579.75.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
Receivables Turnover: 2.04
GF Value™: Rp579.75 vs. price of Rp442.00 (23.8% below fair value)
Industry Position: 56.8% below the Medical Distribution median (#28 of 118)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
57GF Score
Get the complete analysis for ISX:KAEF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
